Body composition shifts with age — a hormonal lens
Why body composition changes after 35 at the same calories and training. The hormonal axes — GH, sex steroids, insulin, thyroid, cortisol — that drive it.
May 7, 2026 · 8 min read · By Strength Peptide Editors
Body composition shifts with age are one of the most visible features of middle adulthood and one of the most over-attributed to single causes. The pop-fitness frame is usually about calories and training. The medical frame is sometimes about thyroid or testosterone. The actual picture is multi-axis: GH, sex steroids, insulin, thyroid, cortisol, and sleep are all drifting at once, and the body composition the user sees in the mirror at 45 is the integral of all of them. This piece walks through each axis in turn, what it does to body composition, and why interventions that address only one layer often disappoint.
What "shifts with age" actually means
The composite pattern, common across most adults from the late 30s onward:
- Lean mass decreases at roughly 0.5–1% per year by middle age, accelerating later
- Fat mass increases, especially central / visceral fat
- Bone density drops gradually, more sharply post-menopause in women
- Connective tissue turns over more slowly; tendon stiffness changes
- Skin elasticity declines
- Resting metabolic rate drops, partly as a consequence of less lean mass
Note the calorie story: at the same caloric intake, the same person at 45 typically has more fat and less lean mass than at 25. The intake didn't change; the body's allocation of those calories did.
The GH axis
The GH-axis decline starts in the late 20s to mid-30s and continues. Its body composition effects:
- Reduced lipolysis, especially in visceral fat, where GH receptors are dense
- Smaller protein-synthesis pulses overnight, especially in the first deep sleep cycle
- Reduced collagen turnover in skin and connective tissue
- Modest insulin sensitivity changes as the GH/insulin balance shifts
The Tesamorelin clinical record — visceral fat reduction in HIV-associated lipodystrophy — is the cleanest demonstration that intervening in the GH axis can move visceral fat specifically. It doesn't generalize to "GH peptides melt fat in healthy adults," but it does demonstrate the axis matters for that specific compartment. See Tesamorelin protocol.
For the broader GH-aging picture, what happens to growth hormone after 35 is the dedicated treatment.
The sex steroid axis
For men, total and especially free testosterone trend down through adulthood at variable rates. The body composition effects:
- Reduced lean mass at the same training stimulus
- Increased fat mass, with some shift toward central adiposity
- Lower training drive in some users, which compounds the lean-mass effect
- Bone density changes at lower endogenous testosterone
For women, the perimenopausal and postmenopausal estrogen decline drives a different but equally real pattern:
- Loss of subcutaneous fat in some compartments, gain in central fat
- Bone density acceleration downward post-menopause
- Insulin sensitivity changes, especially with the central adiposity shift
- Lean mass loss at a higher rate than premenopausal years
Sex steroids and the GH axis are coupled. Estrogen modulates GH; testosterone supports IGF-1; sex steroid decline often shows up as GH-axis-looking symptoms because the systems overlap.
The insulin and metabolic axis
The slow drift toward insulin resistance is one of the most common and least-discussed aging stories. It's not a binary; it's a long gradient.
| Marker | 20s | 50s |
|---|---|---|
| Fasting insulin | Low-normal | Mid-to-upper-normal common |
| Postprandial glucose | Returns to baseline quickly | Slower return |
| Visceral fat | Low | Higher in most |
| Insulin sensitivity | High | Lower |
This drift is partly a consequence of changing body composition (more visceral fat is itself insulin-resistance-promoting), partly genetic, partly diet and activity, and partly age-related changes in mitochondrial function and tissue insulin signaling. The body composition feedback loop is tight: insulin resistance promotes visceral fat, visceral fat promotes insulin resistance.
Anyone working on body composition in middle age who isn't tracking fasting insulin and HbA1c is missing one of the most informative axes.
The thyroid axis
Thyroid is the easy-to-miss layer. Subclinical hypothyroidism is common in middle age, particularly in women, and it produces a recognizable composite: weight gain at the same intake, reduced energy, lower training capacity, dry skin, and fatigue. It also blunts the GH axis indirectly.
Treating an undiagnosed subclinical thyroid issue often produces more body-composition effect than any peptide protocol. The lab work — TSH, free T4, free T3, sometimes reverse T3 and antibodies — is cheap and informative and frequently skipped.
The cortisol axis and sleep
Cortisol rhythm flattens with age in many people: the morning peak gets less defined, the evening trough less complete. Combined with the sleep architecture changes that come along, this produces:
- More central adiposity (cortisol drives visceral fat deposition)
- Reduced overnight recovery signaling
- Compressed slow-wave sleep, which compresses the largest GH pulse
- Mid-night wake in some users, fragmenting the rest of the night
The cortisol-GH-sleep triangle is one system. Pulling on any vertex moves the others, and the most reliable vertex to pull on is sleep — the GH and cortisol curves both follow.
How the axes interact
The honest picture of body composition aging is that no single axis acts alone:
| Axis | Direction with age | Body comp effect |
|---|---|---|
| GH/IGF-1 | Down | Less lean mass, more visceral fat |
| Testosterone (men) | Down | Less lean mass, more fat |
| Estrogen (women) | Down (sharply post-menopause) | Central fat shift, bone loss, lean mass loss |
| Insulin sensitivity | Down | More visceral fat, harder cut |
| Thyroid | Sometimes down | Slower metabolism, fatigue, fat gain |
| Cortisol rhythm | Flatter | Central adiposity, sleep disruption |
The 45-year-old who's gaining belly fat at the same calories has some weighted combination of all of these going on. Asking "is it my testosterone?" or "is it my GH?" frames the question too narrowly. The right question is which axes have moved the most, and which are most accessible to intervene on.
What this means for interventions
The hierarchy of body composition interventions in middle age, from highest leverage to lowest:
1. Sleep and stress
The base layer. Most other axes degrade visibly under chronic sleep loss and elevated cortisol.
2. Resistance training
Direct stimulus for lean mass preservation. The single largest non-pharmacologic lever for the lean-mass side of the equation.
3. Nutrition adequacy
Protein at meaningful intake (1.6–2.2 g/kg lean body mass) supports lean mass; modest caloric discipline supports fat-side composition. Both matter.
4. Treating subclinical issues
Thyroid, sleep apnea, low testosterone with symptoms — these are diagnosable conditions with established treatments and outsized body comp effects.
5. GH peptides
For users whose IGF-1 is in the lower-mid range, who've addressed the layers above, and whose specific issue is recovery, sleep architecture, or visceral fat — GH peptides have a defensible role. They are not the first lever to pull. See GH peptides for fat loss.
6. TRT
For men with diagnosed hypogonadism (numerically and symptomatically), TRT is the relevant intervention for the testosterone axis. This is not a peptide; it's a different protocol with its own profile.
The peptide-first user tends to be disappointed because the upstream layers haven't been addressed. The peptide-last user tends to be satisfied because by the time they start, everything else is already aligned.
A specific note on visceral fat
Visceral fat — the fat around organs, distinct from subcutaneous fat — deserves its own attention. It's metabolically active, drives much of the insulin-resistance feedback loop, and is the compartment most responsive to GH-axis intervention.
Tesamorelin's HIV-LD record is specifically about visceral fat. The Ipamorelin + CJC-1295 stack at higher doses produces some visceral fat shift in long-running users. MK-677 does not, despite raising IGF-1, possibly because of the compound's other effects.
For the user whose body comp issue is specifically visceral, the GH-axis is one of the more responsive levers. For users whose issue is general subcutaneous fat distributed across the body, training and nutrition do most of the work.
The framework
Think of body composition in middle age as a multi-axis stock-and-flow. The stocks are lean mass, fat mass, bone density, and connective tissue. The flows are the hormones and lifestyle factors continually shifting them. The pop story focuses on calories in / calories out as if there's only one input. The actual system has at least six.
The user who understands this:
- Doesn't expect peptides to fix what training and sleep won't
- Doesn't expect training and sleep to fix what's actually a thyroid issue
- Doesn't expect testosterone to fix what's actually visceral-fat-driven insulin resistance
- Tracks the right markers (IGF-1, fasting insulin, HbA1c, free T, TSH, sleep) rather than just the scale
- Adjusts one layer at a time and watches the markers
Middle-age body composition isn't a decline you reverse. It's a system you keep aligning.
Related reading
Free weekly newsletter
Get the strength peptide highlights, weekly.
One short email a week — new guides, study readouts, supply updates, and dosing tips. Plain-English, no spam.
Unsubscribe anytime. We never share your email.